What is ABT-737?

ABT-737 is a BH3 mimetic inhibitor that acts on Bcl-xL, Bcl-2, and Bcl-w. In cell-free assays, the EC50Chemicalbookbooks were 78.7nM, 30.3nM, and 197.8nM, respectively; But it has no inhibitory effect on Mcl-1, Bcl-B, and Bfl-1. It is the first generation of anti apoptotic BCL-2 family protein small molecule inhibitors.

Basic Information

Product Name: ABT-737

CAS: 852808-04-9

MF:C42H45ClN6O5S2

MW:813.43

MDL No.:MFCD12756212

Appearance: Light Yellow to Yellow powder

Purity: 98%+

Package: 1g; 5g; 100g

MOQ: 1g

Origin: China

Used: lab research

Stability: Stable

Delivery Time: 3-7days

Structural formula:

Technical Specification:

Biological activity

ABT-737 is a BH3 mimetic inhibitor that acts on Bcl-xL, Bcl-2, and Bcl-w. In cell-free experiments, the EC50 values were 78.7nM, 30.3nM, and 197.8nM, respectively; But it has no inhibitory effect on Mcl-1, Bcl-B, and Bfl-1.

It upregulates the expression of apoptosis related gene Bim through the JNK/c-Jun signaling pathway, inducing apoptosis in Hela cells.

Detect the growth inhibitory effect of ABT737 on human cervical cancer Hela cells using MTT assay; Detection of cell apoptosis rate using flow cytometry; Use Western blot method to detect the expression of JNK, photo JNK, c-Jun, photo c-Jun, and Bim proteins; Use RT-PCR to detect changes in Bim mRNA levels; Use JNK specific inhibitor SP600125 and siRNA transient transfection to inhibit the activity of JNK and c-Jun.

It can inhibit the growth of Hela cells and induce apoptosis in HeLa cells. It can activate JNK kinase activity and its downstream target molecule c-Jun. The expression of apoptosis related gene Bim is also upregulated at both mRNA and protein levels. After the application of JNK specific inhibitor SP600125 and siRNA targeting JNK and c-Jun to inhibit the activity or expression of JNK or c-Jun, it induced upregulation of Bim and cell apoptosis were effectively blocked.

What is the function of ABT-737?

It is a small molecule compound that is primarily used as a therapeutic agent in cancer treatment. Its primary function is to act as a potent inhibitor of B-cell lymphoma 2 (Bcl-2) proteins, which are known to play a major role in the development and progression of various types of cancer.

By inhibiting these proteins, it helps to induce apoptosis (cell death) in cancer cells, thereby preventing their growth and spread. It has been shown to be particularly effective in treating hematological malignancies such as leukemia, lymphoma, and multiple myeloma, although it may also have applications in solid tumor cancers.

It is typically administered in combination with other chemotherapy drugs, as part of a larger treatment regimen. It has been shown to significantly improve patients' overall response rates and survival outcomes, both in preclinical studies and in clinical trials.

Despite its efficacy, it may have some limitations and potential side effects. For example, it may not be effective in tumors that do not express high levels of Bcl-2 proteins. Additionally, it may cause myelosuppression (a decrease in the number of blood cells) and gastrointestinal toxicity, although these side effects are generally manageable.

Overall, it represents an important advance in cancer therapy, with significant potential for improving patient outcomes. Its ability to specifically target cancer cells, without harming healthy cells, makes it an attractive candidate for further research and clinical development.

What is the Application of ABT-737?

ABT737 is a small molecule inhibitor that has been developed for the treatment of cancer. This molecule functions by targeting Bcl-2 family proteins, which play a critical role in regulating programmed cell death, or apoptosis. Specifically, it binds to the BH3 domain of these proteins, which leads to a disruption of their function and stimulation of apoptosis. As a result, this drug has shown potent anti-tumor activity in preclinical studies.

Its application has primarily been studied in the context of hematologic malignancies, such as lymphoma and leukemia. Early clinical trials have shown promising results in these indications, with some patients experiencing partial or complete responses to treatment. However, its use has also been explored in solid tumors, including melanoma and small cell lung cancer, which are often resistant to standard chemotherapy regimens.

Its mechanism action makes it an attractive therapeutic candidate, as it specifically targets cancer cells without affecting healthy cells. Additionally, the molecule has demonstrated synergistic effects with other anti-cancer agents, such as rituximab and vincristine. These findings suggest that it may serve as a valuable component of combination therapies for cancer treatment.

Despite its potential efficacy, its development has faced some challenges. One major limitation of this compound is its poor solubility, which has hindered its ability to be administered effectively in human studies. Furthermore, its selectivity for Bcl-2 family proteins may limit its utility in patients with tumors that do not overexpress these targets.

In summary, it is an exciting new drug that shows promise as a cancer therapeutic. Its specific mechanism of action and ability to synergize with other agents make it an attractive component of combination regimens. Although development of this compound is ongoing, the results of early clinical trials are encouraging and underscore its potential to improve outcomes for cancer patients.

Packing & Shipping

Payment Term

Why Choose Xi'an Yihui?

Customer feedback

Xi'an Yihui certificates

Welcome to Xi'an Yihui Factory

Our Advantage

Rich experience: we have 13 Years of professional experience;

Customers all over the world: sell to more than 100 countries;

Provide diversified products: the products have been applied to all major international brands in the fields of drugs, dietary supplements, cosmetics, animal nutrition and functional food.

Price advance: low MOQ with competitive price;

Quality certification: ISO; Halal; Kosher certified

After-sales service: Professional team 7*24 hours customer service.

Contact Us:

Yihui takes pride in being a trusted ABT 737 manufacturer and supplier. To acquire this groundbreaking product or discuss your specific requirements, contact us immediately at sales@yihuipharm.com. Rest assured, with Yihui, you're accessing a product of unparalleled quality, backed by certifications that underscore our commitment to excellence in the global market.